Skip to main content
Log in

Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

Teriparatide [rhPTH (1–34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated patients had reduced incidence of back pain relative to placebo or to antiresorptive drugs. The aim of this study was to evaluate back pain in teriparatide-treated versus comparator-treated patients during an interval including controlled clinical trials plus 30 months of additional follow-up.

Methods

A meta-analysis of four completed randomized, double-blinded trials of teriparatide [rhPTH (1–34)] versus comparator was performed. A multivariate Cox proportional hazards model was used to assess the heterogeneity of results and to estimate the relative risk of back pain.

Results

Patients in the pooled teriparatide group had reduced risk for any back pain [relative risk, 0.73 (95% CI, 0.61–0.87)], moderate or severe back pain [0.72 (0.58–0.89)], and severe back pain [0.39 (0.25–0.61)] compared with pooled controls, from initiation of the study drug through the end of follow-up. Sensitivity analysis showed that the results were robust to the removal of each individual trial from the meta-analysis. Separate meta-analyses comparing teriparatide versus placebo or antiresorptive drugs gave similar results.

Conclusions

Teriparatide-treated patients had a reduced incidence of back pain versus those receiving a comparator during an observation encompassing clinical trials plus 30 months of posttreatment observation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S–511S

    Article  PubMed  CAS  Google Scholar 

  2. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128(10):793–800

    PubMed  CAS  Google Scholar 

  3. Cooper C, Atkinson EJ, O'Fallon WM (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7:221–227

    Article  PubMed  CAS  Google Scholar 

  4. Fink HA, Milavetz DL, Palermo L et al (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20:1216–1222

    Article  PubMed  Google Scholar 

  5. Silverman SL, Piziak VK, Chen P et al (2005) Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 32(12):2405–2409

    PubMed  Google Scholar 

  6. Genant HK, Halse J, Briney WG et al (2005) The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 21(7):1027–1034

    Article  PubMed  CAS  Google Scholar 

  7. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(3 Suppl):185S–189S

    Article  PubMed  CAS  Google Scholar 

  8. Edmond SL, Kiel DP, Samelson EJ et al (2005) Vertebral deformity, back symptoms, and functional limitations among older women: the Framingham study. Osteoporos Int 6(9):1086–1095

    Google Scholar 

  9. Ismail AA, Cooper C, Felsenberg D et al (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European vertebral osteoporosis study group. Osteoporos Int 9(3):206–213

    Article  PubMed  CAS  Google Scholar 

  10. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441

    Article  PubMed  CAS  Google Scholar 

  11. Lindsay R, Scheele WH, Neer R et al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(18):2024–2030

    Article  PubMed  Google Scholar 

  12. Miller PD, Shergy WJ, Body JJ et al (2005) Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32(8):1556–1562

    PubMed  CAS  Google Scholar 

  13. Nevitt MC, Chen P, Dore RK et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17(2):273–280

    Article  PubMed  Google Scholar 

  14. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9–17

    Article  PubMed  CAS  Google Scholar 

  15. Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528–4535

    Article  PubMed  CAS  Google Scholar 

  16. Ste-Marie LG, Schwartz SL, Hossain AM et al (2006) Effect of teriparatide [rh parathyroid hormone (1–34)] on bone density when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21(2):283–291

    Article  PubMed  CAS  Google Scholar 

  17. Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16(5):510–516

    Article  PubMed  CAS  Google Scholar 

  18. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(suppl 3):185–189

    Article  Google Scholar 

  19. Cooper C (1993) Epidemiology and public health impact of osteoporosis. Clin Rheumatol 7:459–477

    CAS  Google Scholar 

  20. Andersson GB (1999) Epidemiological features of chronic low-back pain. Lancet 354:581–585

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the assistance of Mindy Rance with the figures and Asad Rand for statistical support. Funding for this study was provided by Lilly Research Laboratories, Eli Lilly and Company.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. H. Krege.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nevitt, M.C., Chen, P., Kiel, D.P. et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 17, 1630–1637 (2006). https://doi.org/10.1007/s00198-006-0177-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0177-z

Keywords

Navigation